GB0224917D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0224917D0
GB0224917D0 GBGB0224917.5A GB0224917A GB0224917D0 GB 0224917 D0 GB0224917 D0 GB 0224917D0 GB 0224917 A GB0224917 A GB 0224917A GB 0224917 D0 GB0224917 D0 GB 0224917D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
compounds
organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0224917.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0224917.5A priority Critical patent/GB0224917D0/en
Publication of GB0224917D0 publication Critical patent/GB0224917D0/en
Priority to TW092129162A priority patent/TW200420545A/zh
Priority to PE2003001076A priority patent/PE20040779A1/es
Priority to ARP030103870A priority patent/AR043055A1/es
Priority to PCT/EP2003/011848 priority patent/WO2004037796A2/en
Priority to PL03374893A priority patent/PL374893A1/xx
Priority to EP03809328A priority patent/EP1558594A2/en
Priority to CNA2009101474324A priority patent/CN101570517A/zh
Priority to KR1020057006954A priority patent/KR20050065620A/ko
Priority to CA2502633A priority patent/CA2502633C/en
Priority to AU2003296559A priority patent/AU2003296559B2/en
Priority to MXPA05004348A priority patent/MXPA05004348A/es
Priority to RU2005115964/04A priority patent/RU2347782C2/ru
Priority to CNB2003801020110A priority patent/CN100554257C/zh
Priority to JP2004545990A priority patent/JP2006505575A/ja
Priority to US10/532,331 priority patent/US7645760B2/en
Priority to BR0315662-1A priority patent/BR0315662A/pt
Priority to ZA200502700A priority patent/ZA200502700B/en
Priority to EC2005005745A priority patent/ECSP055745A/es
Priority to NO20052487A priority patent/NO20052487L/no
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB0224917.5A 2002-10-25 2002-10-25 Organic compounds Ceased GB0224917D0 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
GBGB0224917.5A GB0224917D0 (en) 2002-10-25 2002-10-25 Organic compounds
TW092129162A TW200420545A (en) 2002-10-25 2003-10-21 1-(4-benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives
PE2003001076A PE20040779A1 (es) 2002-10-25 2003-10-23 Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona
ARP030103870A AR043055A1 (es) 2002-10-25 2003-10-23 Derivados de 1-(4-benzil-piperazin-1-il)-3- fenil-propenona
BR0315662-1A BR0315662A (pt) 2002-10-25 2003-10-24 Derivados de 1-(4-benzil-piperazin-1-il)-3-fenil-propenona
KR1020057006954A KR20050065620A (ko) 2002-10-25 2003-10-24 1-(4-벤질-피페라진-1-일)-3-페닐-프로페논 유도체
CNB2003801020110A CN100554257C (zh) 2002-10-25 2003-10-24 1-(4-苄基-哌嗪-1-基)-3-苯基-丙烯酮衍生物
EP03809328A EP1558594A2 (en) 2002-10-25 2003-10-24 1-(4-benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives
CNA2009101474324A CN101570517A (zh) 2002-10-25 2003-10-24 1-(4-苄基-哌嗪-1-基)-3-苯基-丙烯酮衍生物
PCT/EP2003/011848 WO2004037796A2 (en) 2002-10-25 2003-10-24 1-(4-benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives
CA2502633A CA2502633C (en) 2002-10-25 2003-10-24 1-(4-benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives
AU2003296559A AU2003296559B2 (en) 2002-10-25 2003-10-24 1-(4-benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives
MXPA05004348A MXPA05004348A (es) 2002-10-25 2003-10-24 Derivdos de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona.
RU2005115964/04A RU2347782C2 (ru) 2002-10-25 2003-10-24 Производные 1-(4-бензилпиперазин-1-ил)-3-фенилпропенона и их применение, фармацевтическая композиция и способ ингибирования рецепторов хемокина (ccr-1)
PL03374893A PL374893A1 (en) 2002-10-25 2003-10-24 1-(4-benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives
JP2004545990A JP2006505575A (ja) 2002-10-25 2003-10-24 １−（４−ベンジルピペラジン−１−イル）−３−フェニルプロペノン誘導体
US10/532,331 US7645760B2 (en) 2002-10-25 2003-10-24 1-(4-Benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives
ZA200502700A ZA200502700B (en) 2002-10-25 2005-04-04 1-(4-benzyl-piperazin-1-YL)-3-phenyl-propenone derivatives.
EC2005005745A ECSP055745A (es) 2002-10-25 2005-04-25 Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona
NO20052487A NO20052487L (no) 2002-10-25 2005-05-24 1-(4-benzyl-piperazin-1-yl)-3-fenyl-propenonderivater.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0224917.5A GB0224917D0 (en) 2002-10-25 2002-10-25 Organic compounds

Publications (1)

Publication Number Publication Date
GB0224917D0 true GB0224917D0 (en) 2002-12-04

Family

ID=9946616

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0224917.5A Ceased GB0224917D0 (en) 2002-10-25 2002-10-25 Organic compounds

Country Status (19)

Country Link
US (1) US7645760B2 (https=)
EP (1) EP1558594A2 (https=)
JP (1) JP2006505575A (https=)
KR (1) KR20050065620A (https=)
CN (2) CN100554257C (https=)
AR (1) AR043055A1 (https=)
AU (1) AU2003296559B2 (https=)
BR (1) BR0315662A (https=)
CA (1) CA2502633C (https=)
EC (1) ECSP055745A (https=)
GB (1) GB0224917D0 (https=)
MX (1) MXPA05004348A (https=)
NO (1) NO20052487L (https=)
PE (1) PE20040779A1 (https=)
PL (1) PL374893A1 (https=)
RU (1) RU2347782C2 (https=)
TW (1) TW200420545A (https=)
WO (1) WO2004037796A2 (https=)
ZA (1) ZA200502700B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
SE0400441D0 (sv) 2004-02-25 2004-02-25 Active Biotech Ab Novel Benzofurans and Indols
SE0400440D0 (sv) * 2004-02-25 2004-02-25 Active Biotech Ab Novel Cinnamic Amides
GB0409236D0 (en) * 2004-04-26 2004-05-26 Novartis Ag Organic compounds
US7777035B2 (en) 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
CN101007794B (zh) * 2006-01-26 2010-09-01 中国科学院上海药物研究所 N,n'-二取代哌嗪类衍生物及其制备方法、药物组合物和用途
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
US7615556B2 (en) 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
FR2902426B1 (fr) * 2006-06-19 2008-09-05 Pierre Fabre Medicament Sa Derives de cinnamoyl-piperazine
WO2008090357A2 (en) * 2007-01-24 2008-07-31 Palatin Technologies, Inc. N, n; -substituted piperazines binding to melanocortin receptor
TWI433838B (zh) 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
HRP20141190T1 (hr) * 2010-01-29 2015-01-30 Otsuka Pharmaceutical Co., Ltd. Disupstituirani derivati piridina kao antikancerogena sredstva
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity
ES2682217T3 (es) 2012-08-08 2018-09-19 Mitsubishi Tanabe Pharma Corporation Método para producir un compuesto de 1,4-benzoxazina
US9993497B2 (en) * 2012-12-30 2018-06-12 Hadasit Medical Research Services And Development Ltd. Use of alginate compositions in preventing or reducing liver damage caused by a hepatotoxic agent
AP2016009020A0 (en) * 2013-07-18 2016-02-29 Novartis Ag Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
WO2015048570A2 (en) * 2013-09-26 2015-04-02 Sanford-Burnham Medical Research Institute Ebi2 modulators
WO2016116875A1 (en) * 2015-01-20 2016-07-28 Novartis Ag Pet imaging agents
EP4065112A4 (en) * 2019-11-22 2023-12-27 The Regents of the University of California Taspase1 inhibitors and uses thereof
US20230062100A1 (en) 2019-11-28 2023-03-02 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60139646A (ja) * 1983-12-27 1985-07-24 Otsuka Pharmaceut Factory Inc ナフタレン誘導体
JPS6219577A (ja) * 1985-07-16 1987-01-28 Kanebo Ltd 新規なベンジルピペラジン誘導体および該化合物を有効成分とする医薬組成物
SE8803429D0 (sv) * 1988-09-28 1988-09-28 Pharmacia Ab Novel pyridyl- and pyrimidyl derivatives
SE9201956D0 (sv) * 1992-06-25 1992-06-25 Kabi Pharmacia Ab Novel nicotinicacid esters
US5380726A (en) * 1993-01-15 1995-01-10 Ciba-Geigy Corporation Substituted dialkylthio ethers
FR2725445B1 (fr) * 1994-10-10 1996-10-31 Adir Nouveaux derives a structure 1-arylalkenyl 4-aryl alkyl piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2000086603A (ja) * 1998-07-15 2000-03-28 Yoshitomi Pharmaceut Ind Ltd 桂皮酸アミド誘導体および３―フェニルプロピオン酸アミド誘導体
US6110922A (en) * 1998-12-29 2000-08-29 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
OA12670A (en) * 2001-10-22 2006-06-20 Pfizer Prod Inc Piperazine derivatives with ccr1 receptor antagonist activity.

Also Published As

Publication number Publication date
ECSP055745A (es) 2005-07-06
WO2004037796A2 (en) 2004-05-06
US7645760B2 (en) 2010-01-12
NO20052487D0 (no) 2005-05-24
RU2347782C2 (ru) 2009-02-27
KR20050065620A (ko) 2005-06-29
RU2005115964A (ru) 2006-01-27
CA2502633C (en) 2011-02-01
CA2502633A1 (en) 2004-05-06
NO20052487L (no) 2005-05-24
WO2004037796A3 (en) 2004-06-17
AR043055A1 (es) 2005-07-13
BR0315662A (pt) 2005-08-30
TW200420545A (en) 2004-10-16
CN100554257C (zh) 2009-10-28
CN101570517A (zh) 2009-11-04
PE20040779A1 (es) 2004-12-21
EP1558594A2 (en) 2005-08-03
AU2003296559A1 (en) 2004-05-13
US20060173004A1 (en) 2006-08-03
MXPA05004348A (es) 2005-08-02
CN1708489A (zh) 2005-12-14
JP2006505575A (ja) 2006-02-16
AU2003296559B2 (en) 2007-11-01
ZA200502700B (en) 2006-05-31
PL374893A1 (en) 2005-11-14

Similar Documents

Publication Publication Date Title
GB0203276D0 (en) Organic compounds
GB0202873D0 (en) Organic compounds
GB0205281D0 (en) Organic compounds
GB0224917D0 (en) Organic compounds
GB0209481D0 (en) Organic compounds
GB0203061D0 (en) Organic compounds
GB0202874D0 (en) Organic compounds
GB0211261D0 (en) Organic compounds
GB0204756D0 (en) Organic compounds
GB0210535D0 (en) Organic compounds
GB0209257D0 (en) Organic compounds
GB0205537D0 (en) Organic compounds
GB0207496D0 (en) Organic compounds
GB0203189D0 (en) Organic compounds
GB0202755D0 (en) Organic compounds
GB0204752D0 (en) Organic compounds
GB0204754D0 (en) Organic compounds
GB0202381D0 (en) Organic compounds
GB0204763D0 (en) Organic compounds
GB0204765D0 (en) Organic compounds
GB0204766D0 (en) Organic compounds
GB0205023D0 (en) Organic compounds
GB0205280D0 (en) Organic compounds
GB0201913D0 (en) Organic compounds
GB0201881D0 (en) Organic compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)